We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Vascular Sensitivity to Adrenergic Agonists in Patients With CHF and in Healthy Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00782782
Recruitment Status : Unknown
Verified October 2008 by Hadassah Medical Organization.
Recruitment status was:  Active, not recruiting
First Posted : October 31, 2008
Last Update Posted : October 31, 2008
Information provided by:
Hadassah Medical Organization

Brief Summary:
Congestive Heart failure (CHF) is asociated with changes in cardiac function and vascular responses. The aim of this study is to characterize these differences. Our hypothesis is, that there are differences in vascular responses between healthy subjects and patients with CHF.

Condition or disease
Congestive Heart Failure

Study Type : Observational
Estimated Enrollment : 80 participants
Observational Model: Case Control
Time Perspective: Prospective
Official Title: Effect of Medications on Vascular Response in Patients With CHF and in Healthy Subjects
Study Start Date : August 2008
Estimated Primary Completion Date : December 2009
Estimated Study Completion Date : December 2011

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Heart Failure
U.S. FDA Resources

Primary Outcome Measures :
  1. vascular sensitivity (ED50) and response (Emax) to dexmedetomidine, phenylephrine, isoproterenol and terbutaline [ Time Frame: 3 weeks ]

Biospecimen Retention:   Samples Without DNA
samples for norepinephrine and PRA will be retained

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Patients with congestive heart failure NYHA I-II and healthy subjects

Inclusion Criteria:

  • Patients with congestive heart failure NYHA I-II
  • Stable clinical condition

Exclusion Criteria:

  • Resting systolic blood pressure < 100
  • Resting heart rate < 50
  • Hypersensitivity to dexmedetomidine, phenylephrine, isoproterenol, terbutaline

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00782782

Hadassah University Hospital
Jerusalem, Israel, 92110
Sponsors and Collaborators
Hadassah Medical Organization
Principal Investigator: Mordechai Muszkat Hadassah University Hospital

Responsible Party: Mordechai Muszkat, Hadassah University Hospital
ClinicalTrials.gov Identifier: NCT00782782     History of Changes
Other Study ID Numbers: 366-28.12.07
First Posted: October 31, 2008    Key Record Dates
Last Update Posted: October 31, 2008
Last Verified: October 2008

Additional relevant MeSH terms:
Heart Failure
Heart Diseases
Cardiovascular Diseases
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs